Renaissance Technologies
XBIO icon

Renaissance Technologies’s Xenetic Biosciences XBIO Stock Holding History

Renaissance Technologies’s Portfolio XBIO Stock Details XBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$128K Sell
55,040
-62,400
-53% -$196K ﹤0.01% 2982
2026
Q2 		$342K Sell
117,440
-20,000
-15% -$61.8K ﹤0.01% 2733
2026
Q1 		$368K Sell
137,440
-41,069
-23% -$101K ﹤0.01% 2732
2025
Q4 		$387K Buy
178,509
+149,559
+517% +$477K ﹤0.01% 2677
2025
Q3 		$90.9K Buy
28,950
+4,200
+17% +$13.7K ﹤0.01% 3266
2025
Q2 		$97K Sell
24,750
-2,014
-8% -$5.82K ﹤0.01% 3301
2025
Q1 		$69.9K Buy
26,764
+1,214
+5% +$4.75K ﹤0.01% 3243
2024
Q4 		$102K Buy
25,550
+9,700
+61% +$39.1K ﹤0.01% 3283
2024
Q3 		$68.5K Buy
+15,850
New +$62.4K ﹤0.01% 3314
2023
Q3 		– Sell
-25,782
Closed -$85K – 4171
2023
Q2 		$85K Buy
25,782
+15,831
+159% +$59K ﹤0.01% 3508
2023
Q1 		$40K Sell
9,951
-4,389
-31% -$21.3K ﹤0.01% 3707
2022
Q4 		$41K Buy
14,340
+2,830
+25% +$12.5K ﹤0.01% 3841
2022
Q3 		$62K Sell
11,510
-3,596
-24% -$28.4K ﹤0.01% 3704
2022
Q2 		$121K Sell
15,106
-4,035
-21% -$32.6K ﹤0.01% 3799
2022
Q1 		$195K Sell
19,141
-6,981
-27% -$72.8K ﹤0.01% 3659
2021
Q4 		$337K Sell
26,122
-15,767
-38% -$252K ﹤0.01% 3289
2021
Q3 		$859K Buy
41,889
+27,767
+197% +$757K ﹤0.01% 2631
2021
Q2 		$288K Sell
14,122
-10,993
-44% -$222K ﹤0.01% 3159
2021
Q1 		$548K Buy
25,115
+8,095
+48% +$213K ﹤0.01% 2877
2020
Q4 		$347K Buy
17,020
+11,099
+187% +$134K ﹤0.01% 2985
2020
Q3 		$54K Sell
5,921
-11,399
-66% -$123K ﹤0.01% 3269
2020
Q2 		$177K Buy
17,320
+908
+6% +$8.62K ﹤0.01% 3186
2020
Q1 		$122K Buy
16,412
+4,332
+36% +$50.3K ﹤0.01% 3191
2019
Q4 		$174K Buy
+12,080
New +$153K ﹤0.01% 3221

Other funds holding XBIO

HRT Financial
HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
JTC Employer Solutions Trustee
JTC Employer Solutions Trustee St Helier, Jersey $1.16B AUM 24.39% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $273B AUM 15.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Darwin Wealth Management
Darwin Wealth Management Tampa, Florida $378M AUM 15.4% 1-Year Est. Return

Renaissance Technologies's XBIO Position: Q3 2026 in Review

Renaissance Technologies reduced its Xenetic Biosciences (XBIO) stake by 53% in Q3 2026, selling an estimated $196K and leaving 55,040 shares worth $128K. The position accounts for ﹤0.01% of the portfolio, ranked #2982.

Renaissance Technologies first reported a position in XBIO in Q4 2019 and has held it in 24 quarters since. The position peaked at $859K in Q3 2021. 12 funds tracked by Wall St. Rank hold XBIO as of Q3 2026.

  • Renaissance Technologies held 55,040 shares of Xenetic Biosciences worth $128K as of Q3 2026.
  • Renaissance Technologies sold 62,400 Xenetic Biosciences shares in Q3 2026, an estimated $196K.
  • Xenetic Biosciences made up ﹤0.01% of Renaissance Technologies's portfolio in Q3 2026, its #2982 holding.
  • Renaissance Technologies first reported a position in Xenetic Biosciences in Q4 2019 and has held it in 24 quarters since.
  • Renaissance Technologies's Xenetic Biosciences position peaked at $859K in Q3 2021.
  • 12 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q3 2026.

Based on Renaissance Technologies's 13F filing for Q3 2026, filed 12 Nov 2026.